The pathway hyperactivation occurs mainly due to oncogenic mutations in PIK3CA gene encoding the p110a catalytic subunit of the PI3Kα heterodimeric protein complex, observed in approximately 40% of HR + /HER2- BC patients [2]. The gene discussed is PIK3CA; the disease is breast cancer.